SpaceX ($SPCX) and Rocket Lab ($RKLB) share a launch theme, but their listed shares represent different businesses. SpaceX trades as SPCX following its June IPO; it is no longer a private-company comparison. Its group includes connectivity and AI alongside rockets. Rocket Lab combines launch with a substantial space-systems business.
This Monday edition uses completed October 16 regular-session prices, June-quarter financial statements and separately dated subsequent company updates. Neither Friday's prices nor June's cash balances are being presented as new Monday observations.
What each share actually owns
For the quarter ended June 30, SpaceX reported $7.814 billion of revenue: $4.291 billion in Connectivity, $2.561 billion in AI and $962 million in Space. Connectivity includes Starlink. The AI segment includes X advertising and other services; it is not a clean measure of AI-software sales. SpaceX Q2 results.
Rocket Lab reported $234.066 million of Q2 revenue, comprising $189.480 million from space systems and $44.586 million from launch services. More than four-fifths came from space systems. Comparing the two stocks as if each were simply a ticket on a competing rocket misses most of their reported revenue.
Both reported GAAP operating losses: $143 million for SpaceX and $57.514 million for Rocket Lab, or 1.83% and 24.57% of their respective revenues. Those are comparable definitions applied to different businesses and scales, not a complete ranking of business quality.
SpaceX's $3.538 billion of adjusted EBITDA is a different measure from its GAAP operating result. Depreciation, amortization and stock compensation help explain the gap; that adjusted figure should not be described as cash left for shareholders. SpaceX filing · Rocket Lab Q2 results.
Match the cash periods before comparing the funding bill
For the six months ended June 30, SpaceX reported $3.466 billion of operating cash flow against $28.476 billion of cash purchases of property and equipment. Subtracting those lines gives negative $25.010 billion.
Rocket Lab's same six-month operating cash flow was negative $134.407 million, with $53.112 million of property, equipment and software purchases. The corresponding subtraction is negative $187.519 million. Rocket Lab Q2 filing.
These are explicitly defined analytical subtractions, not interchangeable company free-cash-flow measures or total financing needs. They leave out other lines, including SpaceX's separately reported product rebates and capitalized interest, lease principal, acquisitions, and Rocket Lab's asset-disposal proceeds. Their role is to show the cash-investment scale using the same six-month window.
At June 30, SpaceX held $100.009 billion of cash and marketable securities, after $85.675 billion of net IPO proceeds. Rocket Lab held $2.388 billion of cash and marketable securities, with restricted cash excluded. Equity fundraising is financing; neither balance proves the operations funded the buildout. At that same date, reported carrying borrowings were $38.285 billion for SpaceX and $14.845 million for Rocket Lab, excluding finance leases on both sides. Lease obligations remain separate. This is not a total-obligations or post-acquisition comparison; SpaceX also reports related-party financing associated with failed sale-and-leaseback arrangements.
The share counts and businesses have changed since those snapshots. SpaceX completed its Cursor acquisition on August 14, with common-share consideration plus vested-RSU shares and assumed awards. Rocket Lab's September 15 update reported completion of an ATM raising approximately $1.944 billion gross through 29.3 million shares. Gross proceeds should not simply be added to June cash and labelled a current balance.
The next milestones are already different
SpaceX has confirmed Q3 results for October 20 after the close. That report is the next checkpoint for the growing AI investment bill, connectivity economics and consolidated cash generation. Official announcement.
Rocket Lab's October 14 update moved Neutron's expected inaugural launch to 2027. The older Q4 2026 target is superseded. Its announced Iridium acquisition remains pending, with the September update pointing to an expected mid-2027 completion. September 24 shareholder approval is a milestone, not completion. Construction, testing, approvals and future execution still matter.
This distinguishes two real company developments from the separate Tesla–SpaceX merger speculation. Our comparison does not assume any Tesla–SpaceX transaction.
SPCX: a rebound, but still below the near-term averages
SPCX closed October 16 at $146.03, down 10.17% from October 9. Its completed 20-day SMA was $155.24 and 50-day $148.15. Only 88 listed sessions were available, so a 200-day SMA is unavailable. We have not joined pre-IPO valuations onto the daily chart.
The June 16 closing peak was $211.39; the subsequent August 5 closing low was $108.27, a 48.78% decline. The recovery from that low to October 16 was 34.88%. That rebound does not erase the earlier drawdown or establish that near-term weakness has ended.
Friday's $142.96 intraday low is a dated lower reference. Overhead, the October 15 daily gap at $149.04–$151.10 sits near the dated 50-day average. Reclaiming an area and sustaining daily closes above it would be different evidence from merely trading into it.
RKLB: the latest close is the post-peak low
RKLB closed at $50.84, down 25.47% for the week, below its 20-day SMA at $68.37, 50-day at $69.23, and 200-day at $81.26.
Its retained closing peak was $150.23 on May 27, 2026. October 16 was the subsequent closing low, a 66.16% decline. There has been no subsequent closing rebound to measure at this cutoff. Friday's intraday low was $50.37; it is a different price basis.
The October 15 gap at $55.40–$58.84 is an overhead repair reference. None of these prices is a guaranteed floor or destination. Our daily-retest definition requires the test and a daily close back above the relevant level.
Using the same June 12 first-close to October 16 window, SPCX fell 9.27%, RKLB 50.35%, and QQQ 1.60%, excluding dividends. That is a price comparison over a shared window, not a portfolio backtest; it also differs from measuring SPCX against the IPO offer price.
A lower share price does not make one company cheaper. Business mix, outstanding shares, financing obligations and the cash required before the next milestone belong beside the charts. The current evidence supports comparing those separate tests rather than treating either stock as a substitute for the other.
SPCX charts · RKLB charts · All comparisons
Market research only, not a recommendation to buy or sell.